[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"TriHealth Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":190},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,61,89,114,143,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100622722","phase-4-a-randomized-placebo-controlled-trial-of-nitrous-oxide-during-in-office-bladder-botox-injections-100622722",false,"NCT07387315","A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","A Randomized, Placebo Controlled Trial of Nitrous Oxide\u002FOxygen Plus Standard Care Versus Standard Care Alone During In-office Intradetrusor onabotulinumtoxinA (Botox) Injections","Inclusion Criteria:\n\n* Adult women ≥18 years old scheduled for in-office intradetrusor botulinum toxin injection and able to consent.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected vitamin B12 or folate deficiency or high-risk state (e.g., pernicious anemia, malabsorption, post-bariatric or strict vegan without supplementation)\n* currently pregnant\n* severe\u002Funstable pulmonary disease or baseline hypoxemia requiring supplemental home oxygen\n* eye or ear surgery in the last six weeks\n* trapped-air conditions (e.g., untreated pneumothorax, bowel obstruction)\n* severe active otitis\u002Fsinus disease\n* inability to follow directions\n* history of adverse reaction to nitrous oxide","FEMALE","18 Years",{"count":19,"type":20},96,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure?\n\nResearchers will compare a 50:50 nitrous oxide\u002Foxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain.\n\nParticipants will:\n\n* Receive their bladder Botox injection in the office setting\n* Either use nitrous oxide\u002Foxygen plus standard care during the procedure, or sham mask plus standard care\n* Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure",[26,27,28,29,30,31,32,33,34,35],"Overactive Bladder","Neurogenic Bladder","Urge Incontinence","Pain","Urinary Incontinence","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Bladder Neurogenesis","Urinary Incontinence, Urge","Pelvic Floor Disorders",[26,30,28,37,38,39,40,41,42,43,44,45,46,47],"Intradetrusor Injection","OnabotulinumtoxinA","Botox","Bladder Botox","Botulinum Toxins, Type A","Pain Management","Analgesia","Nitrous Oxide","Office-based Procedures","Urogynecology","Pelvic Floor Disorder","NOT_YET_RECRUITING","2026-01-28",{"date":51,"type":52},"2026-02-04","ACTUAL",{"date":54,"type":20},"2026-02",{"date":56,"type":20},"2026-12",{"name":58,"class":59},"TriHealth Inc.","OTHER",2,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":60},"100612995","phase-2-use-of-topical-testosterone-and-estrogen-vs-estrogen-alone-in-vulvodynia-a-randomized-controlled-trial-100612995","NCT07260825","Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years or older\n* Patients with vulvodynia who present with pain (with vaginal penetration) rating score of 4 or greater\n\nExclusion Criteria:\n\n* Active vaginal infection\n* Pregnancy\n* Breast-feeding\n* Taking anti-androgenic medication (finasteride, dutasteride)\n* Using any other topical hormones to the vulva or vagina",{"count":68,"type":20},44,[70,71],"PHASE2","PHASE3","We are looking to see if patients using both topical testosterone and estrogen will have a greater improvement in pain with vaginal penetration compared to those using topical estrogen alone.",[74,75,76],"Vulvodynia","Dyspareunia","Lichen Sclerosus of Vulva",[78,79,80],"topical testosterone","estrogen cream","vulvodynia","2025-11-21",{"date":83,"type":52},"2025-12-03",{"date":85,"type":20},"2025-12",{"date":87,"type":20},"2026-08",{"name":58,"class":59},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100594321","vitamin-d-and-hypertensive-disorders-of-pregnancy-100594321","NCT07017920","Vitamin D and Hypertensive Disorders of Pregnancy","The Relationship Among Vitamin Deficiency\u002FInsufficiency, Vitamin Supplementation, and Hypertensive Disorders of Pregnancy","Inclusion Criteria:\n\n* Pregnant women\n* 18-45 years old\n* Receiving care at outpatient OB office of TriHealth's Women's Services Comprehensive OB-GYN Team with a plan to deliver at Bethesda North Hospital\n\nExclusion Criteria:\n\n* Non-English speaking\n* Unable to provide consent to research study participation\n* Diagnosis of preexisting renal disease\n* Diagnoses of preexisting chronic hypertension\n* Diagnosis of cardiovascular diseases\n* Diagnosis of conditions limiting fat absorption\n* Diagnosis of sarcoidosis","45 Years",{"count":98,"type":20},594,[100],"NA","The purpose of this study is to further investigate the association between vitamin D deficiency\u002Finsufficiency and hypertensive disorders of pregnancy by studying the impact of screening for vitamin D deficiency and supplementation when low levels of vitamin D are detected. Screening for vitamin D deficiency (less than 20 ng\u002FmL) and insufficiency (less than 30 ng\u002FmL) may determine the need for additional supplementation, as most prenatal vitamins only contain 400 IU of vitamin D. The rates of hypertensive disorders of pregnancy amongst patients who received supplementation and maintained adequate vitamin D levels will be followed.",[103],"Hypertensive Disorders of Pregnancy",[105],"vitamin D","2025-06-04",{"date":108,"type":52},"2025-06-12",{"date":110,"type":20},"2025-07-01",{"date":112,"type":20},"2027-12-31",{"name":58,"class":59},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":121,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100584423","impact-of-nmn-supplementation-on-cd4-t-cell-recovery-in-hiv-patients-with-immunological-failure-100584423","NCT06889142","Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure","Proof-of-Concept Study: Investigating the Impact of NMN Supplementation on CD4+ T Cell Recovery in Virologically Suppressed HIV Patients With Immunological Failure","Inclusion Criteria:\n\n* HIV-infected adults aged 18 years or older\n* Virologically suppressed on ART documented with two negative viral loads separated by at least 6 months\n* Confirmed diagnosis of immunological failure (CD4+ T cell count \\\u003C350 cells\u002FµL 2 years after effective ART initiation)\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Active opportunistic infections\n* Known allergies or sensitivities to NMN or any components of the NMN supplement\n* Current or recent use of other supplements or medications known to affect NAD+ metabolism (Niacin, NR, NMNH, etc.)\n* Pregnancy or breastfeeding\n* Significant liver or kidney disease\n* Active malignancy\n* History of uncontrolled substance abuse\n* Severe medical conditions that might interfere with study participation\n* Unable to consent","ALL",{"count":123,"type":20},7,[100],"This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppressed HIV patients experiencing immunological failure on ART. We hypothesize that NMN supplementation will increase intracellular NAD+ levels, thereby improving CD4+ T cell function and potentially reversing immunological failure. A small cohort of patients will be recruited to evaluate the primary outcome of change in CD4+ T cell count from baseline to the end of the study period after receiving NMN daily for 12 weeks. Secondary outcomes including safety and tolerability, impact on pro-inflammatory markers, increase in NAD+ levels, immune activation markers and change in quality of life questionnaire scores. Patients will participate in two in person visits including a baseline and end of study with two telephone encounters. Patients will take 1,000mg NMN daily for a total of 12 weeks during which they will keep a daily log of doses taken and any side effects experienced. At all visits labs and quality of life questionnaire will be completed with complete physical exam to be done at baseline and end of study visit.",[127],"Human Immunodeficiency Virus",[129,130,131,132,133,134],"HIV","immunologic failure","proof of concept","CD4+ T cell recovery","immunological non-responders","Nicotinamide Mononucleotide","2025-03-31",{"date":137,"type":52},"2025-04-03",{"date":139,"type":20},"2025-04",{"date":141,"type":20},"2025-07",{"name":58,"class":59},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100580917","phase-3-peri-operative-tamsulosin-and-impact-on-voiding-trial-after-same-day-urogynecology-surgery-100580917","NCT06843538","Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery","Peri-operative Tamsulosin and Impact on Voiding Trial Following Outpatient Urogynecology Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n\\- Patients undergoing any pelvic organ prolapse repair or incontinence surgery\n\nExclusion Criteria:\n\n* Any surgery involving a non-urogynecologist\n* Patients already on an alpha blocker\n* Baseline hypotension\n* History of syncope\n* Postural orthostatic tachycardia syndrome (POTS)\n* Non-English speaker or interpreter unavailable for Spanish-speaking patient\n* Impaired cognition impeding proper consenting\n* Any other medical contraindication for tamsulosin use\n* History of urinary retention requiring continuous or intermittent catheterization\n* Patients consented for the study but then due to intraoperative complication, routine voiding trial no longer indicated due to requiring indwelling catheter or intermittent catheterization on discharge will be excluded from primary outcome analysis\n* Pregnancy",{"count":151,"type":20},166,[71],"The purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a Foley catheter (flexible tube that drains urine from the bladder into a collection bag).",[155],"Postoperative Urinary Retention (POUR)","RECRUITING","2025-02-20",{"date":159,"type":52},"2025-02-25",{"date":161,"type":52},"2025-02-03",{"date":163,"type":20},"2026-06-01",{"name":58,"class":59},1,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":165},"100547908","histologic-comparison-of-ablative-techniques-for-endometriosis-100547908","NCT06414083","Histologic Comparison of Ablative Techniques for Endometriosis","Histologic Comparison of Ablative Techniques for Endometriosis - a Randomized Trial","Inclusion Criteria:\n\n* Adult women 18 years of age or older\n* Already planning to undergo scheduled robotic assisted or laparoscopic excision of lesions for pelvic pain symptoms (pelvic pain, dysmenorrhea, dyspareunia, dysuria, dyschezia, ovarian pain) or endometriosis of any kind (endometriosis of any location, or endometrioma)\n\nExclusion Criteria:\n\n* Known pregnancy at enrollment or at the time of the excision surgery",{"count":174,"type":20},141,[100],"To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.",[178,179,180,181],"Endometriosis","Endometriosis-related Pain","Endometriosis Pelvic","Endometriosis; Peritoneum","2024-05-28",{"date":184,"type":52},"2024-05-30",{"date":186,"type":52},"2024-05-09",{"date":188,"type":20},"2025-06-09",{"name":58,"class":59},""]